Craig E. Fraser
Net Worth

Last updated:

What is Craig E. Fraser net worth?

The estimated net worth of Mr. Craig E. Fraser is at least $6,957,490 as of 27 Sep 2023. He owns shares worth $27,850 as insider and has received compensation worth at least $6,929,640 in Windtree Therapeutics, Inc..

What is the salary of Craig E. Fraser?

Mr. Craig E. Fraser salary is $769,960 per year as Pres, Chief Executive Officer & Director in Windtree Therapeutics, Inc..

How old is Craig E. Fraser?

Mr. Craig E. Fraser is 60 years old, born in 1965.

What stocks does Craig E. Fraser currently own?

As insider, Mr. Craig E. Fraser owns shares in one company:

Company Title Shares Price per share Total value
Windtree Therapeutics, Inc. (WINT) Pres, Chief Executive Officer & Director 57,877 $0.48 $27,850

What does Windtree Therapeutics, Inc. do?

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

WINT logo
WINT
Windtree Therapeutics, Inc.
$0.48

Craig E. Fraser insider trading

Windtree Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 2,500 $1.02 $2,550
Purchase
Common Stock 2,500 $0.9 $2,250
Purchase
Common Stock 1,497 $1.77 $2,650
Purchase
Common Stock 1,315 $1.89 $2,485
Purchase
Common Stock 2,500 $0.38 $950
Purchase
Common Stock 2,500 $0.37 $935
Purchase
Common Stock 4,500 $0.43 $1,926
Purchase
Common Stock 7,000 $0.42 $2,905
Purchase
Common Stock 2,000 $0.98 $1,960
Purchase
Common Stock 3,000 $0.98 $2,940
Purchase
Common Stock 930 $1.6 $1,488
Purchase
Common Stock 930 $1.61 $1,497
Purchase
Common Stock 3,000 $1.9 $5,700
Purchase
Common Stock 3,000 $1.91 $5,730
Purchase
Common Stock 1,000 $2.09 $2,092
Purchase
Common Stock 1,000 $2.24 $2,240
Purchase
Common Stock 500 N/A N/A
Purchase
Common Stock 1,000 $2.58 $2,580
Purchase
Common Stock 500 $2.46 $1,230
Purchase
Common Stock 500 $2.32 $1,160
Purchase
Common Stock Warrants 1,500 N/A N/A
Purchase
Common Stock 1,500 $3.6 $5,400
Purchase
Common Stock 250 $6.56 $1,640
Purchase
Common Stock 250 $5.83 $1,456
Purchase
Common Stock 250 $5.17 $1,293
Purchase
Common Stock 2,069 $7.98 $16,500
Purchase
Common Stock Warrants 2,069 $7.98 $16,500
Purchase
Common Stock 250 $4.1 $1,025
Purchase
Common Stock 250 $4.1 $1,025
Purchase
Common Stock 500 N/A N/A
Purchase
Common Stock 100 N/A N/A
Purchase
Series A-1 Warrants (Right to Buy) 7,000 N/A N/A
Purchase
Series A Convertible Preferred Stock 7 N/A N/A
Purchase
Common Stock 7,500 N/A N/A

Windtree Therapeutics key executives

Windtree Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Mr. Craig E. Fraser (60) Pres, Chief Executive Officer & Director
  • Mr. Eric L. Curtis M.B.A. (57) Senior Vice President & Chief Operating Officer
  • Mr. John P. Hamill (61) Senior Vice President, Chief Financial Officer & Corporation Sec.